GoKawiil
Tech News
Boston Longevity Week, an 11-day series of events including biomarker conferences, an AI hackathon and an investor pitch night with over 30 venture firms, culminates in a Translational Longevity Summit. The event's organizers argue the longevity field's core challenge isn't a lack of innovation or even regulation, but a failure to translate promising research into validated, clinically usable treatments.
Researchers at Collaborations Pharmaceuticals found their AI drug-discovery tool could generate 40,000 potentially toxic chemical warfare molecules in under six hours, some more lethal than known nerve agents. The finding, first reported in 2022, is now cited by biosecurity experts as evidence that AI systems and increasingly accessible gene-editing tools could lower the barrier to creating dangerous biological or chemical agents.
Researchers led by Stanford computer scientist James Zou built a system called Virtual Biotech, using up to 37,000 AI agents modeled like departments of a biotech company, overseen by a 'chief scientific officer' agent. After analyzing thousands of past clinical trials, the AI swarm flagged an immune-dampening protein as a target and, with human guidance, proposed a candidate treatment for lung cancer, detailed in a new Science paper.
Montana has enacted SB535, a law that extends right-to-try provisions by allowing physicians to administer treatments that have cleared FDA Phase 1 trials outside formal clinical trials, provided a state-registered review board approves the protocol and care is delivered at a licensed clinic. Unlike federal right-to-try or expanded access rules, the Montana law permits sponsors and clinics to charge patients for these treatments, addressing what backers call the core funding gap facing biotech firms after early trials.
Investors are reportedly re-entering rare-disease drug stocks after the departure of stricter FDA regulators under the Trump administration. The shift in agency leadership has reduced concerns about tougher approval hurdles that had previously discouraged investment in this biotech segment.
Chinese pharmaceutical companies, once known mainly for producing cheap generic medicines, are now developing original obesity and weight-loss drugs aimed at competing with Western blockbusters like Ozempic and Wegovy. Several firms are advancing candidates through clinical trials and striking licensing deals with major international drugmakers.
Fast Company released its Best Workplaces for Innovators 2026 list for the biotech, healthcare, and life sciences category, naming 10 companies as top honorees. Five of those winning companies are based in the Boston area, underscoring the region's concentration of biotech talent and innovation.
Vijay Pande, who built Andreessen Horowitz's biotech investing practice into a nearly $4 billion operation, has departed to co-found a much smaller firm called VZVC with longtime investor Zach Werner. The new fund makes only a handful of concentrated investments each year instead of dozens, forgoes associates, and leans heavily on AI tools to run its operations.